Targeting immune checkpoints in glioblastoma treatment
Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody
['FUNDING_R01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-11088753
This study is looking at a new treatment for glioblastoma, a tough brain tumor, by using a special antibody to help your immune system fight the cancer better by blocking certain pathways that the tumor uses to hide.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11088753 on ClinicalTrials.gov |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain tumor, and aims to enhance the body's immune response against it using a novel bispecific antibody. The approach involves targeting specific immune checkpoints that glioblastoma cells exploit to evade the immune system, particularly the CD47 and β2 microglobulin pathways. By blocking these checkpoints, the research seeks to improve the effectiveness of cancer immunotherapy, potentially leading to better outcomes for patients with this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who have not responded well to conventional therapies.
Not a fit: Patients with non-glioblastoma brain tumors or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, improving survival rates and quality of life for patients.
How similar studies have performed: While there have been some successes in targeting immune checkpoints in other cancers, the specific approach for glioblastoma using bispecific antibodies is still being explored and is considered novel.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JIANG, WEN — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: JIANG, WEN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anticancer immunotherapy